Search

Investment of 65 million euro in avian vaccines in France

Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines

Covid Global Support Programm

COVID-19: Boehringer Ingelheim steps up effort with Global Support Program

Winners of BVDzero Scholarship Programme

Boehringer Ingelheim announces winners of BVDzero Scholarship Programme

Promising phase II results in chronic kidney disease

Boehringer Ingelheim’s investigation of novel compound on top of standard of care empagliflozin shows promising results for chronic kidney disease

Phase 1 start of treatment for Geographic Atrophy patients

Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)

Drug Discovery at Boehringer Ingelheim

Find out more about the drug discovery process at Boehringer Ingelheim

LastMile initiative to address barriers in animal healthcare

The ‘LastMile’ initiative addresses major barriers in animal healthcare sector in Sub-Saharan African

Boehringer expands production site in Greece

Boehringer expands production site in Greece for new medicine

Green Chemistry

Green Chemistry is critical for us as it balance the long-term sustainability of business, society, and the environment.

Production Insights

Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals

discontinuation-bi-1467335-diabetic-retinopathy

The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced

License to develop new fibro-inflammatory disease treatments

License deal with A*STAR to develop cancer antibodies

Making a difference with data science

Our Head of Central Data Science, Brigitte Fuhr joined the team to make a difference to patients’ lives.

Global Top Employer 2023

Kicking off 2024 with five new R&D partnerships

We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.

2024 half year results innovation progress

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Boehringer Ingelheim Access to Healthcare Strategy last mile

We aspire to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world.

A tool to aid in the prevention of African swine fever

ASF COMBAT is an online management and biosecurity assessment tool aimed at reducing the African swine fever introduction risk level.

opening-solids-launch-fabrik

Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.

World Rabies Day 2020 sustainable dog vaccination

Ingelheim

The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.

Celebrating 20 years of Metacam for cattle

Celebrating 20 years of Metacam (Meloxicam) for cattle

cat feline diabetes medication treatment fda approval

Boehringer Ingelheim receives FDA approval for SENVELGO®

Launch of BVDzero scholarship for veterinary students

Launch of BVDzero scholarship for veterinary students globally

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers